CoChat
Sign Up
Cited by 130

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases

Wang, Qing, Yan, Junqiang, Chen, Xiaohong, Li, Jin, Yang, Yu, Weng, JianPing, Deng, Chao, Yenari, Midori A·2011·Experimental Neurology
DOI 10.1016/j.expneurol.2010.04.006
Open this paper in CoChat — free account

Abstract

Statins have been widely used for the treatment of a variety of conditions beyond their original role in lowering cholesterol. Since statins have relatively few side effects, they have been recognized as useful medicine to ameliorate neurodegenerative disorders. Current studies on the applications of statins have demonstrated their neuroprotective and clinical significance among neurodegenerative diseases like cerebral ischemic stroke, vascular dementia, Alzheimer's disease, and Parkinson's disease, though the neuroprotective mechanisms are not completely understood. This review will discuss recent development in the use of statins in slowing down the progression of these neurodegenerative diseases. It will summarize the potential mechanisms for statin-mediated neuroprotective effects in neurodegenerative diseases. In detail, this review discuss the roles of statins in lowering cholesterol, reducing reactive oxygen species, impairing β-amyloid production and serum apolipoprotein E levels, enhancing the levels of endothelial nitric oxide synthase and cerebral blood flow, and modulating cognitive related receptors and matrix metalloproteases. Finally, different alterations of various receptors in brain regions following statin treatment and their correlations with cognitive dysfunction in Parkinson's disease will also be reviewed, as well as the potential for therapy in ameliorating the progression of Parkinson's disease. This article is part of a Special Issue entitled "Intera…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2010.04.006

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 114

  1. Aelst, 1997, Rho GTPases and signaling networks, Genes Dev., 11, 2295, 10.1101/gad.11.18.2295 · DOI
  2. Aloisi, 2001, Immune function of microglia, Glia, 36, 165, 10.1002/glia.1106 · DOI
  3. Amarenco, 2009, Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial, Stroke, 40, 2486, 10.1161/STROKEAHA.108.546135 · DOI
  4. Aoki, 2008, Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats, Stroke, 39, 1276, 10.1161/STROKEAHA.107.503086 · DOI
  5. Asahi, 2005, Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia, J. Cereb. Blood Flow Metab., 25, 722, 10.1038/sj.jcbfm.9600070 · DOI
  6. Assini, 2004, Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment, Neurology, 63, 828, 10.1212/01.WNL.0000137040.64252.ED · DOI
  7. Bar-On, 2008, Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease, J. Neurochem., 105, 1656, 10.1111/j.1471-4159.2008.05254.x · DOI
  8. Becker, 2008, Use of statins and the risk of Parkinson's disease: a retrospective case–control study in the UK, Drug Saf., 31, 399, 10.2165/00002018-200831050-00004 · DOI
  9. Berger, 2008, Neuroprotection by pravastatin in acute ischemic stroke in rats, Brain Res. Rev., 58, 48, 10.1016/j.brainresrev.2007.10.010 · DOI
  10. Bonarek, 2000, Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study, Neuroepidemiology, 19, 141, 10.1159/000026249 · DOI
  11. Boshuizen, 1998, Blood pressure and mortality in elderly people aged 85 and older: community based study, BMJ, 316, 1780, 10.1136/bmj.316.7147.1780 · DOI
  12. Buxbaum, 2002, Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer B-amyloid peptide in vitro and in patients, Front. Biosci., 7, 50
  13. Buxbaum, 2001, Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide, J. Alzheimer's Dis., 3, 221, 10.3233/JAD-2001-3207 · DOI
  14. Carloni, 2009, Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation, Exp. Neurol., 220, 82, 10.1016/j.expneurol.2009.07.026 · DOI
  15. Carlsson, 2009, Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis, Alzheimer Dis. Assoc. Disord., 23, 11, 10.1097/WAD.0b013e3181850188 · DOI
  16. Carod-Artal, 2006, Statins and cerebral vasomotor reactivity: implications for a new therapy?, Stroke, 37, 2446, 10.1161/01.STR.0000239656.59618.d4 · DOI
  17. Corzo, 2007, Decreased levels of serum nitric oxide in different forms of dementia, Neurosci. Lett., 420, 263, 10.1016/j.neulet.2007.05.008 · DOI
  18. Cui, 2009, Chemokine, vascular and therapeutic effects of combination simvastatin and BMSC treatment of stroke, Neurobiol. Dis., 36, 35, 10.1016/j.nbd.2009.06.012 · DOI
  19. Di Napoli, 2002, Statins and stroke: evidence for cholesterol-independent effects, Eur. Heart J., 23, 1908, 10.1053/euhj.2002.3236 · DOI
  20. Endo, 1976, ML-236A, ML-236B, ML-236C, new inhibitors of cholesterogenesis produced by Pennicillium citrinum, J. Antibiot., 29, 1346, 10.7164/antibiotics.29.1346 · DOI
  21. Endres, 1998, Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. U. S. A., 95, 8880, 10.1073/pnas.95.15.8880 · DOI
  22. Endres, 2004, Targeting eNOS for stroke protection, Trends Neurosci., 27, 283, 10.1016/j.tins.2004.03.009 · DOI
  23. Erdös, 2006, Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production, Am. J. Physiol, Heart Circ. Physiol., 290, H1264, 10.1152/ajpheart.00804.2005 · DOI
  24. Evans, 2000, Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans, Neurology, 54, 240, 10.1212/WNL.54.1.240 · DOI
  25. Fernández, 2009, Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity, J. Neurosci., 29, 6394, 10.1523/JNEUROSCI.4909-08.2009 · DOI
  26. Furberg, 1999, Natural statins and stroke risk, Circulation, 99, 185, 10.1161/01.CIR.99.2.185 · DOI
  27. Furman, 2004, Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability, Atherosclerosis, 174, 93, 10.1016/j.atherosclerosis.2004.01.009 · DOI
  28. Ghosh, 2009, Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease, J. Neurosci., 29, 13543, 10.1523/JNEUROSCI.4144-09.2009 · DOI
  29. Gianella, 2007, Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats, Am. J. Pathol., 170, 1165, 10.2353/ajpath.2007.060882 · DOI
  30. Gidday, 2005, Leukocyte-derived matrix metalloproteinase-9 mediates blood–brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia, Am. J. Physiol, Heart Circ. Physiol., 289, H558, 10.1152/ajpheart.01275.2004 · DOI
  31. Glorioso, 1999, Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia, Hypertension, 34, 1281, 10.1161/01.HYP.34.6.1281 · DOI
  32. Gomez-Isla, 1996, Clinical and pathological correlates of apolipoprotein E 4 in Alzheimer's disease, Ann. Neurol., 39, 62, 10.1002/ana.410390110 · DOI · Paper page
  33. Groemping, 2005, Activation and assembly of the NADPH oxidase: a structural perspective, Biochem. J., 386, 401, 10.1042/BJ20041835 · DOI
  34. Grundy, 1988, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N. Engl. J. Med., 319, 24, 10.1056/NEJM198807073190105 · DOI
  35. Guasti, 2008, Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up, Eur. Heart J., 29, 1118, 10.1093/eurheartj/ehn138 · DOI
  36. Gunstad, 2008, beta-Amyloid is associated with reduced cognitive function in healthy older adults, J. Neuropsychiatry, Clin. Neurosci., 20, 327, 10.1176/jnp.2008.20.3.327 · DOI
  37. Haan, 1999, The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons, JAMA, 282, 40, 10.1001/jama.282.1.40 · DOI · Paper page
  38. Handattu, 2009, Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease, Neurobiol. Dis., 34, 525, 10.1016/j.nbd.2009.03.007 · DOI
  39. Heeba, 2009, Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1, Br. J. Pharmacol., 156, 1256, 10.1111/j.1476-5381.2009.00125.x · DOI
  40. Hernández-Romero, 2008, Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide, J. Neurochem., 105, 445, 10.1111/j.1471-4159.2007.05148.x · DOI
  41. Hildebrandt, 2009, False recognition correlates with amyloid-beta (1–42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment, J. Alzheimer's Dis., 16, 157, 10.3233/JAD-2009-0931 · DOI
  42. Hirsch, E. C., Hunot, S., Damier, P., Faucheux, B, 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44(3Suppl 1), S115–120. Review. · DOI
  43. Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
  44. Höglund, 2005, Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease, Exp. Brain Res., 164, 205, 10.1007/s00221-005-2243-8 · DOI
  45. Hong, 2006, Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke, Am. J. Physiol, Heart Circ. Physiol., 291, H2210, 10.1152/ajpheart.01270.2005 · DOI
  46. Hu, 2008, Total cholesterol and the risk of Parkinson disease, Neurology, 70, 1972, 10.1212/01.wnl.0000312511.62699.a8 · DOI
  47. Huang, 2007, Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease, Mov. Disord., 22, 377, 10.1002/mds.21290 · DOI
  48. Ifergan, 2006, Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis, Ann. Neurol., 60, 45, 10.1002/ana.20875 · DOI
  49. Jick, 2000, Statins and the risk of dementia, Lancet, 356, 1627, 10.1016/S0140-6736(00)03155-X · DOI
  50. Kannel, 1997, Blood pressure and cardiovascular morbidity and mortality rates in the elderly, Am. Heart J., 134, 758, 10.1016/S0002-8703(97)70061-9 · DOI
  51. Kario, 1997, Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease, Hypertension, 30, 1504, 10.1161/01.HYP.30.6.1504 · DOI
  52. Kelly, 2006, Matrix metalloproteinase activation and blood–brain barrier breakdown following thrombolysis, Exp. Neurol., 200, 38, 10.1016/j.expneurol.2006.01.032 · DOI
  53. Koladiya, 2008, Ameliorative role of atorvastatin and pitavastatin in l-methionine induced vascular dementia in rats, BMC Pharmacol., 8, 14, 10.1186/1471-2210-8-14 · DOI
  54. Koob, 2010, Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies, Exp. Neurol., 221, 267, 10.1016/j.expneurol.2009.11.015 · DOI
  55. Kunte, 2008, Markers of instability in high-risk carotid plaques are reduced by statins, J. Vasc. Surg., 47, 513, 10.1016/j.jvs.2007.11.045 · DOI
  56. Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat. Med., 6, 1004, 10.1038/79510 · DOI
  57. Laufs, 1997, Inhibition of 3.hydroxy-3methylglutaryl (HMG)-CoA reductase blocks hypoxia mediated down-regulation of endothelial nitric oxide synthase, J. Biol. Chem., 50, 31725, 10.1074/jbc.272.50.31725 · DOI
  58. Laufs, 1998, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, Circulation, 97, 1129, 10.1161/01.CIR.97.12.1129 · DOI
  59. Laufs, 2000, Targeting Rho in cardiovascular disease, Circ. Res., 87, 526, 10.1161/01.RES.87.7.526 · DOI
  60. Li, 2007, Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease, Neurology, 69, 878, 10.1212/01.wnl.0000277657.95487.1c · DOI
  61. Lieberman, 2005, Statins, cholesterol, co-enzyme Q10, and Parkinson's disease, Parkinsonism Relat. Disord., 11, 81, 10.1016/j.parkreldis.2004.07.012 · DOI
  62. Liu, 1996, Palmitoylation of nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization, Biochemistry, 35, 13277, 10.1021/bi961720e · DOI
  63. Liu, 2006, Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection, J. Cereb. Blood Flow Metab., 26, 787, 10.1038/sj.jcbfm.9600227 · DOI
  64. Maack, 2003, Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment, Circulation, 108, 1567, 10.1161/01.CIR.0000091084.46500.BB · DOI
  65. Mann, 1997, Preferential deposition of amyloid beta protein [A] in the form A 40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E 4 allele, Neurosci. Lett., 221, 81, 10.1016/S0304-3940(96)13294-8 · DOI · Paper page
  66. Mayanagi, 2008, Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia, J. Cereb. Blood Flow Metab., 28, 1927, 10.1038/jcbfm.2008.81 · DOI
  67. Mogi, 2007, p53 protein, interferongamma, and NF-kappaB levels are elevated in the parkinsonian brain, Neurosci. Lett., 414, 94, 10.1016/j.neulet.2006.12.003 · DOI
  68. Moro, 2004, Role of nitric oxide after brain ischaemia, Cell Calcium, 36, 265, 10.1016/j.ceca.2004.02.011 · DOI
  69. Mutez, 2009, Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease, Pharmacol. Res., 60, 41, 10.1016/j.phrs.2009.03.010 · DOI
  70. Nakamura, 2006, Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial, Lancet, 368, 1155, 10.1016/S0140-6736(06)69472-5 · DOI · Paper page
  71. Newman, 2005, Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort, J. Am. Geriatr. Soc., 53, 1101, 10.1111/j.1532-5415.2005.53360.x · DOI · Paper page
  72. Nicholson, 2009, Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity, J. Neurosci., 29, 4640, 10.1523/JNEUROSCI.0862-09.2009 · DOI
  73. Ostrowski, 2007, Statins reduce amyloid-beta production through inhibition of protein isoprenylation, J. Biol. Chem., 282, 26832, 10.1074/jbc.M702640200 · DOI · Paper page
  74. Otto, 2006, Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway, Br. J. Pharmacol., 148, 544, 10.1038/sj.bjp.0706738 · DOI
  75. Ovbiagele, 2007, Statin enhancement of collateralization in acute stroke, Neurology, 68, 2129, 10.1212/01.wnl.0000264931.34941.f0 · DOI
  76. Packard, 2007, Association between apolipoprotein E4 and cognitive decline in elderly adults, J. Am. Geriatr. Soc., 55, 1777, 10.1111/j.1532-5415.2007.01415.x · DOI
  77. Panza, 2006, Lipid metabolism in cognitive decline and dementia, Brain Res. Rev., 51, 275, 10.1016/j.brainresrev.2005.11.007 · DOI
  78. Panza, 2006, Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline, Aging Clin. Exp. Res., 18, 144, 10.1007/BF03327430 · DOI
  79. Papassotiropoulos, 2003, Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism, Arch. Neurol., 60, 29, 10.1001/archneur.60.1.29 · DOI
  80. Paterniti, 2000, Low blood pressure and risk of depression in the elderly: a prospective community based study, Br. J. Psychiatry, 176, 464, 10.1192/bjp.176.5.464 · DOI
  81. Prinz, 2008, Intravenous rosuvastatin for acute stroke treatment: an animal study, Stroke, 39, 433, 10.1161/STROKEAHA.107.492470 · DOI
  82. Rikitake, 2005, Rho GTPases, statins, and nitric oxide, Circ. Res., 97, 1232, 10.1161/01.RES.0000196564.18314.23 · DOI
  83. Rockwood, 2002, Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people, Arch. Neurol., 59, 223, 10.1001/archneur.59.2.223 · DOI
  84. Rosenberg, 2002, Matrix metalloproteinases in neuroinflammation, Glia, 39, 279, 10.1002/glia.10108 · DOI
  85. Rosenberg, 2001, Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures, Brain Res., 893, 104, 10.1016/S0006-8993(00)03294-7 · DOI · Paper page
  86. Samii, 2008, Statin use and the risk of Parkinson disease: a nested case control study, J. Clin. Neurosci., 15, 1272, 10.1016/j.jocn.2008.01.016 · DOI
  87. Schuster, 2008, The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease, J. Neurosci., 28, 4311, 10.1523/JNEUROSCI.4720-07.2008 · DOI
  88. Selley, 2005, Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice, Brain Res., 1037, 1, 10.1016/j.brainres.2004.02.083 · DOI
  89. Shaw, 1986, A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation, Cell, 46, 659, 10.1016/0092-8674(86)90341-7 · DOI
  90. Simons, 2001, Cholesterol and Alzheimer's disease: is there a link?, Neurology, 57, 1089, 10.1212/WNL.57.6.1089 · DOI
  91. Sparks, 2006, Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial, Acta Neurol. Scand. Suppl., 185, 3, 10.1111/j.1600-0404.2006.00690.x · DOI
  92. Sparks, 2008, Reduced risk of incident AD with elective statin use in a clinical trial cohort, Curr. Alzheimer Res., 5, 416, 10.2174/156720508785132316 · DOI · Paper page
  93. Sposito, 1999, Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin converting enzyme inhibitors (enalapril or lisinopril), Am. J. Cardiol., 83, 1497, 10.1016/S0002-9149(99)00132-0 · DOI
  94. Sterzer, 2001, Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease, Stroke, 32, 2817, 10.1161/hs1201.099663 · DOI
  95. Stoll, 1999, The role of microglia and macrophages in the pathophysiology of the CNS, Prog. Neurobiol., 58, 233, 10.1016/S0301-0082(98)00083-5 · DOI
  96. Suribhatla, 2005, A study of statin use in the prevention of cognitive impairment of vascular origin in the UK, J Neurol Sci., 229–230, 47
  97. Turner, 2005, Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels, FASEB J., 19, 804, 10.1096/fj.04-2852fje · DOI
  98. Vaughan, 2001, Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?, CNS Drugs, 15, 589, 10.2165/00023210-200115080-00002 · DOI
  99. Wahner, 2008, Statin use and the risk of Parkinson disease, Neurology, 70, 1418, 10.1212/01.wnl.0000286942.14552.51 · DOI
  100. Wang, 2007, Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury, Exp. Neurol., 206, 59, 10.1016/j.expneurol.2007.03.031 · DOI
  101. Wang, 2007, The inflammatory response in stroke, J. Neuroimmunol., 184, 53, 10.1016/j.jneuroim.2006.11.014 · DOI
  102. Wang, 2005, High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase, Br. J. Pharmacol., 144, 933, 10.1038/sj.bjp.0706106 · DOI
  103. Wang, 2005, Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats, Brain Res., 1045, 229, 10.1016/j.brainres.2005.03.016 · DOI
  104. Wang, 2009, High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain, Exp. Neurol., 216, 132, 10.1016/j.expneurol.2008.11.016 · DOI
  105. Wang, 2006, Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes, Stroke, 37, 1910, 10.1161/01.STR.0000226923.48905.39 · DOI
  106. Wassmann, 2001, Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase, Mol. Pharmacol., 59, 646, 10.1016/S0026-895X(24)12257-2 · DOI
  107. Watanabe, 1996, Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese, Stroke, 27, 1319, 10.1161/01.STR.27.8.1319 · DOI
  108. Whitehouse, 1997, Dementia drug development: use of information systems to harmonize global drug development, Psychopharmacol. Bull., 33, 129
  109. Wolozin, 2000, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch. Neurol., 57, 1439, 10.1001/archneur.57.10.1439 · DOI
  110. Wolozin, 2007, Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease, BMC Med., 5, 20, 10.1186/1741-7015-5-20 · DOI
  111. Yaffe, 2002, Serum lipoprotein levels, statin use, and cognitive function in older women, Arch. Neurol., 59, 378, 10.1001/archneur.59.3.378 · DOI
  112. Yamada, 2000, Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment, J. Cereb. Blood Flow Metab., 20, 709, 10.1097/00004647-200004000-00008 · DOI
  113. Yamanouchi, 2005, Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition, J. Vasc. Surg., 42, 757, 10.1016/j.jvs.2005.05.041 · DOI
  114. Zhou, 2009, Rho kinase: an important mediator of atherosclerosis and vascular disease, Curr. Pharm. Des., 15, 3108, 10.2174/138161209789057986 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, Q., Yan, J., Chen, X., Li, J., Yang, Y., Weng, J., Deng, C., & Yenari, M. A.
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2011-07
Volume
230
Issue
1
Pages
27-34
ISSN
0014-4886
DOI
10.1016/j.expneurol.2010.04.006
Cited by
130
References
2
Language
en
Licence
Funders
  • National Health and Medical Research Council (514640)
  • Ministry of Education of the People's Republic of China
  • Sun Yat-sen University (10ykzd08)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review